Angiogenesis using placental stem cells

Patent metadata

Field	Value
Publication number	US-9254302-B2
Application number	US-201113081415-A
Country	US
Kind code	B2
Filing date	Apr 6, 2011
Priority date	Apr 7, 2010
Publication date	Feb 9, 2016
Grant date	Feb 9, 2016

Abstract

Provided herein are methods of treating individuals having diseases or disorders of the circulatory system, using placental cells, e.g., the placental stem cells and placental multipotent cells (PDACs) described herein, and populations of such placental cells. The invention also provides methods of angiogenesis using such cells or populations of cells comprising such cells.

First claim

What is claimed:

1. A method of treating an individual having peripheral arterial disease, critical limb ischemia, diabetic ulcer, or peripheral vascular disease,
comprising:
administering to the individual a population of isolated placental cells, wherein said placental cells (i) adhere to tissue culture plastic; (ii) are CD10+, CD34−, CD105+, and CD200+ as determined by flow cytometry, and (iii) promote the proliferation of endothelial cells; promote the formation of sprouts or tube-like structures in a population of endothelial cells; or promote the migration of endothelial cells;
wherein said administration of cells is in an amount and for a time sufficient for detectable improvement of one or more symptoms of peripheral arterial disease, critical limb ischemia, diabetic ulcer, or peripheral vascular disease.

2. The method of claim 1 , wherein said individual has peripheral vascular disease.

3. The method of claim 2 , wherein said symptom of peripheral vascular disease is cold, tingling feet that turn red upon dangling; pain; or weakness and tiredness in the legs.

4. The method of claim 2 , wherein said placental cells have been passaged at least one time prior to administration to said individual.

5. The method claim of claim 1 , wherein said individual has critical limb ischemia.

6. The method of claim 5 , wherein said symptom of critical limb ischemia is ischemic rest pain; severe pain in the legs and feet while the individual is not moving; non-healing sores on the feet or legs; pain or numbness in the feet; shiny, smooth, dry skin of the legs or feet; thickening of the toenails; absent or diminished pulse in the legs or feet; open sores; skin infections or ulcers that do not heal; or dry gangrene of the legs or feet.

7. The method of claim 5 , wherein said placental cells have been passaged at least one time prior to administration to said individual.

8. The method of claim 1 , wherein said individual has peripheral arterial disease.

9. The method of claim 1 , wherein said placental cells are administered intravenously, intra-arterially, intramuscularly, intradermally, subcutaneously, or locally.

10. The method of claim 1 , comprising administration of about 1×10 5 , 5×10 5 , 1×10 6 , 5×10 6 , 1×10 7 , 5×10 7 , 1×10 8 , 5×10 8 , 1×10 9 , 5×10 9 , or 1×10 10 placental cells.

11. The method of claim 1 , wherein said individual has a diabetic ulcer.

12. The method of claim 1 , wherein said placental cells have been passaged at least one time prior to administration to said individual.

13. The method of claim 11 , wherein said placental cells have been passaged at least one time prior to administration to said individual.

14. A method of treating an individual having a disruption of blood flow in or around a limb, wherein said disruption of blood flow in or around a limb is caused by peripheral arterial disease, critical limb ischemia, or peripheral vascular disease, comprising:
administering to the individual a therapeutically effective amount of placental cells, wherein said placental cells (i) adhere to tissue culture plastic; (ii) are CD10+, CD34−, CD105+, and CD200+ as determined by flow cytometry, and (iii) promote the proliferation of endothelial cells; promote the formation of sprouts or tube-like structures in a population of endothelial cells; or promote the migration of endothelial cells;
wherein said administration of cells results in improvement of blood flow in or around the limb.

15. The method of claim 14 , wherein said disruption of blood flow in or around a limb is peripheral vascular disease.

16. The method of claim 14 , wherein said disruption of blood flow in or around a limb is critical limb ischemia.

17. The method of claim 14 , wherein said disruption of blood flow in or around a limb is peripheral arterial disease.

18. The method of claim 14 , wherein said placental cells are administered intravenously, intra-arterially, intramuscularly, intradermally, subcutaneously, or locally.

19. The method of claim 14 , comprising administration of about 1×10 5 , 5×10 5 , 1×10 6 , 5×10 6 , 1×10 7 , 5×10 7 , 1×10 8 , 5×10 8 , 1×10 9 , 5×10 9 , or 1×10 10 placental cells.

20. The method of claim 14 wherein said placental cells have been passaged at least one time prior to administration to said individual.

Assignees

• Abbot Stewart
• Edinger James W
• Francki Aleksandar
• Hariri Robert J
• Jankovic Vladimir
• Kaplunovsky Aleksandr
• Labazzo Kristen
• Law Eric
• Padliya Neerav D
• Paredes Jennifer
• Wang Jia-Lun
• Anthrogenesis Corp

Inventors

• Abbot Stewart
• Edinger James W
• Francki Aleksandar
• Hariri Robert J
• Jankovic Vladimir
• Kaplunovsky Aleksandr
• Labazzo Kristen
• Law Eric
• Padliya Neerav D
• Paredes Jennifer
• Wang Jia-Lun

Classifications

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title

• A61P7/02

  Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors · CPC title

• A61P9/06

  Antiarrhythmics · CPC title

• A61P9/12

  Antihypertensives · CPC title

• A61P9/04

  Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure · CPC title